Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 28, 2013

Study Reveals Far More Potentially Functional RNA Than Previously Recognized

  • In an RNA-seq-based study, investigators at the University of California, San Francisco, have found that the human genome encodes far more long, intergenic noncoding RNAs (lincRNAs) than were previously known.

    And while lincRNAs had largely been considered genomic “junk”—transcriptional noise—the scientists present in PLOS Genetics new evidence to suggest some may have functional consequences.

    “We found that the lincRNAs we identified have many characteristics that are inconsistent with noise, including specific regulation of their expression, the presence of conserved sequence and evidence for regulated processing,” UCSF’s Michael McManus, Ph.D., and his colleagues write. “Furthermore, these lincRNAs are strongly enriched with intergenic sequences that were previously known to be functional in human traits and diseases.”

    Dr. McManus et al., studied a large set of RNA-seq data covering an array of tissue types and performed de novo transcriptome assembly.

    Overall, the investigators identified tens of thousands of putative lincRNAs expressed at a level of at least one copy per cell. Finding many more lincRNAs than they had anticipated, the researchers write, actually helps “to resolve the discrepancy between the vast amount of observed intergenic transcription and the limited number of previously known lincRNAs.”

    “Now that we realize that all these RNA molecules exist and have identified them, the struggle is to understand which are going to have a function that is important,” Dr. McManus said in a statement. “It may take decades to determine this.”

    “Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs” appeared in PLOS Genetics June 20.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »